Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier
Yelixza I. Avila,
Morgan Chandler,
Edward Cedrone,
Hannah S. Newton,
Melina Richardson,
Jie Xu,
Jeffrey D. Clogston,
Neill J. Liptrott,
Kirill A. Afonin,
Marina A. Dobrovolskaia
Affiliations
Yelixza I. Avila
Nanoscale Science Program, Department of Chemistry, University of North Carolina Charlotte, Charlotte, NC 28223-0001, USA
Morgan Chandler
Nanoscale Science Program, Department of Chemistry, University of North Carolina Charlotte, Charlotte, NC 28223-0001, USA
Edward Cedrone
Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21702, USA
Hannah S. Newton
Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21702, USA
Melina Richardson
Nanoscale Science Program, Department of Chemistry, University of North Carolina Charlotte, Charlotte, NC 28223-0001, USA
Jie Xu
Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21702, USA
Jeffrey D. Clogston
Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21702, USA
Neill J. Liptrott
Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L7 3NY, UK
Kirill A. Afonin
Nanoscale Science Program, Department of Chemistry, University of North Carolina Charlotte, Charlotte, NC 28223-0001, USA
Marina A. Dobrovolskaia
Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21702, USA
Recent insights into the immunostimulatory properties of nucleic acid nanoparticles (NANPs) have demonstrated that variations in the shape, size, and composition lead to distinct patterns in their immunostimulatory properties. While most of these studies have used a single lipid-based carrier to allow for NANPs’ intracellular delivery, it is now apparent that the platform for delivery, which has historically been a hurdle for therapeutic nucleic acids, is an additional means to tailoring NANP immunorecognition. Here, the use of dendrimers for the delivery of NANPs is compared to the lipid-based platform and the differences in resulting cytokine induction are presented.
